Zanzalintinib in Unresectable and Progressive MPGGs

Phase 2 Not yet recruiting 14 enrolled Dana-Farber Cancer Institute Exelixis · collab

NaSingle-groupOpen-labelTreatment

Summary

This study is to examine the effects of oral daily zanzalintinib in participants with unresectable, progressive metastatic pheochromocytoma or paraganglioma.

Timeline

Start: 2027-01-09
Primary completion: 2031-01-01
Completion: 2032-01-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Zanzalintinib	Small molecule	60 mg	Oral

Zanzalintinib in Unresectable and Progressive MPGGs

Summary

Timeline

Drugs

Indications